Why Shares of Novo Nordisk Stock Collapsed This Week

Shares of Novo Nordisk (NYSE: NVO) were down over 20% this week as of this writing on Friday, February 6th, at 11:00 AM EST, according to data from S&P Global Market Intelligence. The famed drugmaker has struggled over the last two years due to heavy competition and pricing pressure for weight-loss drugs. It is also trying to deal with aggressive competition from Hims & Hers. Right now, Novo Nordisk stock is down 68% from all-time highs set in early 2024. Here's why it was falling again this week, and whether it is a buy today. Novo Nordisk reported earnings earlier this week, on February 3rd. Its financials looked solid, with revenue growing 10% year over year in constant currency in 2025, despite heavy pressure from other weight-loss drugmakers such as Eli Lilly. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool